<SEC-DOCUMENT>0001213900-23-027109.txt : 20230404
<SEC-HEADER>0001213900-23-027109.hdr.sgml : 20230404
<ACCEPTANCE-DATETIME>20230404161934
ACCESSION NUMBER:		0001213900-23-027109
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20230404
DATE AS OF CHANGE:		20230404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inspira Technologies OXY B.H.N. Ltd
		CENTRAL INDEX KEY:			0001837493
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-266748
		FILM NUMBER:		23797907

	BUSINESS ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
		BUSINESS PHONE:		972-9-9664488

	MAIL ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>ea176347-424b5_inspira.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Filed pursuant to Rule 424(b)(5)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-266748</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase"><B>PROSPECTUS
</B></FONT><B>SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>(To Prospectus dated August 18, 2022)</B> &nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="img_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to $5,480,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into a sales agreement, or the
Sales Agreement with Roth Capital Partners LLC, or Roth, dated April 4, 2023, relating to the sale of our ordinary shares, no par value
(&ldquo;Ordinary Shares&rdquo;), offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of
the Sales Agreement, we may offer and sell our Ordinary Shares, having an aggregate offering price of up to $5,480,000, from time to time
through or to Roth as sales agent or principal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of our Ordinary Shares, if any, under this
prospectus supplement may be made in sales deemed to be &ldquo;at the market offerings&rdquo; as defined in Rule 415 promulgated under
the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). Roth is not required to sell any specific number or dollar
amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales
practices, on mutually agreed terms between Roth and us. There is no arrangement for funds to be received in any escrow, trust or similar
arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Roth will be entitled to compensation at a commission
rate of 3.0% of the gross sales price per share sold pursuant to the terms of the Sales Agreement. See &ldquo;Plan of Distribution&rdquo;
beginning on page S-12 for additional information regarding the compensation to be paid to Roth in connection with the sale of the Ordinary
Shares on our behalf, Roth will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act, and the compensation
of Roth will be deemed to be underwriting commissions or discounts. We also have agreed to provide indemnification and contribution to
Roth with respect to certain liabilities, including liabilities under the Securities Act or the Exchange Act of 1934, as amended (the
&ldquo;Exchange Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Ordinary Shares are listed on the Nasdaq Capital
Market under the symbol &ldquo;IINN.&rdquo; On March 29, 2023, the last reported sale price of the Ordinary Shares on the Nasdaq Capital
Market was $1.37 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate market value of our outstanding
Ordinary Shares held by non-affiliates was approximately $16.4 million based on 8,700,947 shares of outstanding Ordinary Shares held by
non-affiliates and a price per share of $1.89, the closing price of our Ordinary Shares on February 8, 2023. Pursuant to General Instruction
I.B.5 of Form F-3, we may not sell securities registered on Form F-3 with a value more than one-third of the aggregate market value of
our Ordinary Shares held by non-affiliates in any 12-month period, so long as the aggregate market value of our Ordinary Shares held by
non-affiliates remains less than $75.0 million. As of the date hereof, we have not sold any Ordinary Shares pursuant to General Instruction
I.B.5 of Form F-3 during the prior 12 calendar month period that ends on, and includes, the date hereof.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an emerging growth company, as defined
in the Jumpstart Our Business Startups Act of 2012, and have elected to comply with certain reduced public company reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in the Ordinary Shares involves
risk. See &ldquo;Risk Factors&rdquo; beginning on page S-4 of this prospectus supplement and in the documents incorporated by reference
into this prospectus supplement and the accompanying prospectus for a discussion of information that should be considered in connection
with an investment in the Ordinary Shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state or other foreign securities commission has approved or disapproved of these securities or determined if this prospectus
supplement is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt; background-color: white"><B>Roth
Capital Partners</B></FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus supplement is April
4, 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 10pt"><B>Prospectus Supplement</B></FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#ps_001">About this Prospectus Supplement</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-ii</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#ps_002">Prospectus Supplement Summary</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#ps_003">Risk Factors</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-4</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#ps_004">Cautionary Statement Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-6</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#ps_005">Use of Proceeds</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-8</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#ps_006">Dividend Policy</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-9</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#ps_007">Capitalization</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-10</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#ps_008">Dilution</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-11</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#ps_009">Plan of Distribution</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-12</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#ps_010">Legal Matters</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-14</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#ps_011">Experts</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-14</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#ps_012">Where You Can Find More Information</A> </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-14</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#ps_013">Incorporation of Certain Information by Reference</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-15</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">About this Prospectus</A></FONT></TD>
    <TD STYLE="width: 10%; text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">About Our Company</A></FONT></TD>
    <TD STYLE="text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">Risk Factors</A></FONT></TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">Cautionary Note Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">Capitalization</A></FONT></TD>
    <TD STYLE="text-align: center">4</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">Use of Proceeds</A></FONT></TD>
    <TD STYLE="text-align: center">5</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">Description of Securities</A> </FONT></TD>
    <TD STYLE="text-align: center">6</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">Plan of Distribution</A></FONT></TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">Legal Matters</A></FONT></TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">Experts</A></FONT></TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Expenses</A></FONT></TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">Incorporation of Certain Information by Reference</A></FONT></TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">Where You Can Find More Information</A> </FONT></TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">Enforceability of Civil Liabilities</A></FONT></TD>
    <TD STYLE="text-align: center">14</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ps_001"></A><B>ABOUT THIS PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to
part of a registration statement on Form F-3 that we have filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) utilizing
a &ldquo;shelf&rdquo; registration process. Under this shelf registration process, we may sell the securities described in our base prospectus
included in the shelf registration statement in one or more offerings up to a total aggregate offering price of $50,000,000. As of April
4, 2023, we have not sold any Ordinary Shares under that shelf registration statement. We sometimes refer to the Ordinary Shares as the
&ldquo;securities&rdquo; throughout this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This document contains two
parts. The first part is this prospectus supplement, which describes the terms of this offering of the Ordinary Shares, and also adds,
updates and changes information contained in the accompanying prospectus and the documents incorporated herein and therein by reference.
This prospectus supplement relates only to an offering of up to $5,480,000 of our Ordinary Shares through Roth These sales, if any, will
be made pursuant to the terms of the sales agreement, or the Sales Agreement, entered into between us and Roth on April 4, 2023, a copy
of which will be incorporated by reference into this prospectus supplement. The second part is the accompanying prospectus, which gives
more general information about us, some of which may not apply to this offering. You should read both this prospectus supplement and the
accompanying prospectus, including the information incorporated by reference herein and therein. To the extent the information contained
in this prospectus supplement differs or varies from the information contained in the accompanying prospectus or any document filed prior
to the date of this prospectus supplement and incorporated herein or therein by reference, the information in this prospectus supplement
will control; provided, that if any statement in one of these documents is inconsistent with a statement in another document having a
later date, the statement in the document having the later date modifies or supersedes the earlier statement. In addition, this prospectus
supplement and the accompanying prospectus do not contain all of the information provided in the registration statement that we filed
with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) that contains the accompanying prospectus (including the exhibits
to the registration statement). For further information about us, you should refer to that registration statement, which you can obtain
from the SEC as described elsewhere in this prospectus supplement under &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation
of Certain Information by Reference.&rdquo; You may obtain a copy of this prospectus supplement, the accompanying prospectus and any of
the documents incorporated by reference without charge by requesting it from us in writing or by telephone at the following address or
telephone number: Inspira Technologies Oxy B.H.N. Ltd., 2 Ha-Tidhar St., Ra&rsquo;anana, 4366504 Israel, Israel, Tel: +972 996 644 88.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only on the
information contained in or incorporated by reference into this prospectus supplement and the accompanying prospectus. We have not authorized
anyone to provide you with information that is different. No dealer, salesperson or other person is authorized to give any information
or to represent anything not contained in or incorporated by reference into this prospectus supplement and the accompanying prospectus,
and you must not rely upon any information or representation not contained in or incorporated by reference into this prospectus supplement
or the accompanying prospectus. This prospectus supplement and the accompanying prospectus do not constitute an offer to sell or solicitation
of an offer to buy these securities in any circumstances under which the offer or solicitation is unlawful. We are offering to sell, and
seeking offers to buy, our securities offered hereby only in jurisdictions where offers and sales are permitted. You should not assume
that the information we have included in this prospectus supplement or the accompanying prospectus is accurate as of any date other than
the date of this prospectus supplement or the accompanying prospectus, respectively, or that any information we have incorporated by reference
is accurate as of any date other than the date of the document incorporated by reference, regardless of the time of delivery of this prospectus
supplement and the accompanying prospectus or of any of our securities. Our business, financial condition, results of operations and prospects
may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this prospectus, &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company&rdquo; and &ldquo;Inspira&rdquo; refer to Inspira Technologies Oxy B.H.N. Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our reporting currency is
the U.S. dollar and our functional currency is New Israeli Shekels. Unless otherwise expressly stated or the context otherwise requires,
references in this prospectus to &ldquo;NIS&rdquo; are to New Israeli Shekels, , and references to &ldquo;dollars&rdquo; or &ldquo;$&rdquo;
are to U.S. dollars.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ps_002"></A><B>PROSPECTUS SUPPLEMENT SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This summary highlights
information contained elsewhere or incorporated by reference into this prospectus supplement and the accompanying prospectus. This summary
does not contain all of the information that you should consider before investing in our securities. You should carefully read the entire
prospectus supplement and the accompanying prospectus, including the &ldquo;Risk Factors&rdquo; section, starting on page S-4 of this
prospectus supplement and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus,
as well as the financial statements and notes thereto and the other information incorporated by reference herein and therein, before
making an investment decision.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty medical
device company engaged in the research, development, manufacturing, and marketing of proprietary respiratory support technology that is
intended to reduce the need for invasive mechanical ventilation, or IMV, which is the standard of care today for the treatment of acute
respiratory failure. Although it may be sometimes lifesaving, IMV is associated with increased risks, costs of care, extended lengths
of stay, frequent incidence of infections, ventilator dependence and mortality. Using our state-of-the-art respiratory support technology,
our goal is to set a new standard of care and to provide patients with acute respiratory failure an opportunity to maintain spontaneous
breathing and avoid the need for intubation, coma and various risks associated with the use of IMV. As part of our strategy to reach this
goal, and in parallel to pursuing regulatory approvals, we are actively working to establish collaborations with strategic partners, globally
ranked hospitals, medical device companies and distributors both for endorsement and early clinical adoption. &nbsp;We plan to target
intensive care units, or ICUs, general medical units, operating theaters, emergency medical services and small urban and rural hospitals,
with the goal of making our solutions more accessible to millions of patients worldwide. We expect for these activities to support our
strategy plan to reach market penetration and adoption of our respiratory support technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing the following
products:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>The INSPIRA<SUP>TM</SUP>
ART System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART system (Augmented
Respiratory Technology) (also known as the ART500 or ART), described herein as the INSPIRA ART, INSPIRA ART device or INSPIRA ART system,
our flagship product, is a respiratory support technology targeting to utilize direct blood oxygenation to boost patient saturation levels
within minutes while the patient is awake &amp; spontaneously breathing. The aim of our products is to reduce the need for IMV with the
potential to reduce risks, complications and high costs and potentially allowing for larger patient populations in and beyond ICU settings.
The INSPIRA ART is being designed as a new intent of use for long-term (longer than 6 hours) respiratory support that provides assisted
extracorporeal circulation and physiologic gas exchange (oxygenation and CO2 removal) of the patient&rsquo;s blood in adults with acute
respiratory failure, targeting to allow for treatment of patients while they are awake. The INSPIRA ART is being designed to potentially
prevent the need for invasive mechanical ventilation, targeting acute respiratory failure patients in ICUs and general medical units.
The next generation INSPIRA ART is expected to be submitted to the U.S. Food and Drug Administration, or FDA, for regulatory approval
via the pre-market approval application or De Novo regulatory pathways.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>The HYLA<SUP>TM</SUP> Blood
Sensor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HYLA blood sensor, described
herein as the HYLA or HYLA blood sensor, originally designed as a key and core technology for the INSPIRA ART, is being developed also
as a stand-alone device to be integrated or used in extracorporeal procedures. The HYLA is a non-invasive optical blood sensor designed
to perform real-time and continuous blood measurements, potentially minimizing the need to take actual blood samples from patients. The
HYLA&rsquo;s measurements can assist physicians in the monitoring of patient&rsquo;s clinical condition. The HYLA blood sensor is being
designed as a clip-on sensor, attached to the outer walls of a blood tube, that may potentially reduce risks, complications, and costs.
The HYLA blood sensor may have broad application potential, benefiting patients undergoing procedures such as cardiopulmonary bypass operations,
Extracorporeal Membrane Oxygenation, or ECMO and Cardiopulmonary bypass, pending regulatory approvals.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>The ALICE Device&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ALICE Device (previously
referred to as the Liby or ECLS system), described herein as the ALICE, or the ALICE device, an advanced form of life support system better
known by the medical industry as a cardiopulmonary bypass system, or CPB, is being designed for use in surgical procedures requiring cardiopulmonary
bypass for 6 hours or less. The ALICE device is expected to be submitted to the FDA for 510k clearance, during the second half of 2023.
The ALICE is designed to be a new generation CPB system with potential advantages to medical device design with ergonomic configuration
and intuitive user-centric software and display to increase functionality, as well as a large touchscreen with novel colorful graphical
representation that increases the visibility and functionality of data displayed to the medical staff. The ALICE device is being designed
to be lightweight and highly durable and will be equipped with long battery life to maximize its portability. The ALICE device, designed
as a CPB, shall be indicated for use in surgical procedures requiring cardiopulmonary bypass for 6 hours or less.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a goal to set a new
standard of care in various areas of patient care. As part of our strategy to reach these goals, and in parallel to pursuing regulatory
approvals, we are actively working to establish collaborations with strategic partners and globally ranked health centers to provide endorsement
and clinical adoption for regional deployments of our respiratory support, heart-lung bypass, ECMO and blood monitoring products and technologies.
We plan to target ICUs, general medical units, Operating theaters, emergency medical services and small urban and rural hospitals, with
the goal of making our solutions more accessible to millions of patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an Israeli corporation
based in Ra&rsquo;anana, Israel and were incorporated in Israel in 2018 under the name Clearx Medical Ltd. On April 10, 2018, our name
was changed to Insense Medical Ltd. and on July 30, 2020, our name was changed to our current name, Inspira Technologies Oxy B.H.N. Ltd.
Our principal executive offices are located at 2 Ha-Tidhar St., Ra&rsquo;anana, 4366504 Israel. Our telephone number in Israel is 972
996 644 88. Our website address is&nbsp;<I>www.inspira-technologies.com</I>. The information contained on, or that can be accessed through,
our website is not part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-size: 10pt">Ordinary Shares offered by us</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 58%; text-align: justify"><FONT STYLE="font-size: 10pt">Ordinary Shares, having an aggregate offering price of up to 4 $5,480,000.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Ordinary Shares outstanding prior to the offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">11,700,103 Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Ordinary Shares to be outstanding after this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">15,700,103 Ordinary Shares, assuming sales of $5,480,000 of Ordinary
Shares in this offering at an offering price of $1.37, which is the last reported sale price of the Ordinary Shares on the Nasdaq Capital
Market on March 29, 2023. The actual number of Ordinary Shares will vary, depending on the sales price in this offering.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Manner of Offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;At the market offering&rdquo; that may be made from time to
    time through or to Roth, as sales agent or principal. See &ldquo;Plan of Distribution&rdquo; on page S-12 of this prospectus
    supplement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Use of proceeds </FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to use the net proceeds from the sale
    of securities under this prospectus for general corporate purposes, which include financing our research and development, including human
    observational studies, system engineering and other regulatory approval processes ,business development marketing activities and implementation
    of our commercialization strategy.&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &ldquo;Use of Proceeds&rdquo; on page
S-8 of this prospectus supplement.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Risk factors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Investing in the Ordinary Shares involves a high degree of risk. See
&ldquo;Risk Factors&rdquo; beginning on page S-4 of this prospectus supplement and in the documents incorporated by reference into this
prospectus supplement and the accompanying prospectus for a discussion of the risks you should carefully consider before deciding to
invest in the Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Nasdaq Capital Market symbol</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our Ordinary Shares are listed on the Nasdaq under the symbol &ldquo;IINN.&rdquo; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
the number of ordinary shares outstanding prior to and after this offering is based on 11,700,103 Ordinary Shares outstanding as of March
28, 2023, and excludes the following as of such date:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">471,372 Ordinary Shares issuable upon the exercise of options
to directors, employees and consultants under our equity incentive plan, outstanding as of such date, with exercise prices ranging between
NIS 0.37 (approximately $0.11) to NIS 0.97 (approximately $0.29) per share, and 29,400 Ordinary Shares issuable upon the exercise of
options to consultants under our equity incentive plan, outstanding as of such date, with exercise price of $3.08. 477,761 of the total
options were vested as of such date;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">1,361,056 Restricted Share Units,
or RSUs, granted to directors, employees, and consultants under our equity incentive plan, none of which were vested as of such date;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">36,550 Ordinary Shares reserved for future issuance under our equity incentive plan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">169,016 Ordinary Shares issuable upon the exercise of warrants issued to InSense Medical Pty Ltd. in connection with a certain termination agreement, with an exercise price of $5.50 per Ordinary Share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">795,832 Ordinary Shares issuable upon the exercise of warrants issued in connection with certain equity investment agreements, which we refer to as Simple Agreements for Future Equity, or SAFEs&nbsp;and an additional 3,247 Ordinary Shares issuable upon the exercise of warrants issued to promoters in connection with such SAFEs; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">353,750 Ordinary Shares issuable upon the exercise of warrants issued in connection with a certain convertible loan, and an additional 13,340 Ordinary Shares issuable upon the exercise of warrants issued to promoters in connection with such convertible loan agreements.</FONT></TD></TR>
  </TABLE>


</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ps_003"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Investing in our securities
involves significant risks. Before making an investment decision, you should carefully consider the risks described below and in our most
recent Annual Report on Form 20-F, and in our other SEC filings incorporated by reference into this prospectus supplement and the accompanying
prospectus, and in any amendment or update thereto reflected in our subsequent filings with the SEC and incorporated by reference into
this prospectus supplement and the accompanying prospectus, together with all of the other information appearing in this prospectus supplement
or the accompanying prospectus or incorporated by reference herein or therein, including in light of your particular investment objectives
and financial circumstances. The risks so described are not the only risks we face. Additional risks not presently known to us or that
we currently deem immaterial may also impair our business operations and become material. Our business, financial condition and results
of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any
of these risks, and you may lose all or part of your investment. The discussion of risks includes or refers to forward-looking statements;
you should read the explanation of the qualifications and limitations on such forward-looking statements discussed elsewhere in this prospectus
supplement under the caption &ldquo;Cautionary Statement Regarding Forward-Looking Statements&rdquo; below.</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Since we have broad discretion in how we
use the proceeds from this offering, we may use the proceeds in ways with which you disagree.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the net proceeds
of this offering for working capital and for other general corporate purposes, which include financing our operations, research and development,
including human observational studies, system engineering and other regulatory approval processes, business development marketing activities
and implementation of our commercialization strategy. Accordingly, our management will have significant flexibility in applying the net
proceeds of this offering. You will be relying on the judgment of our management with regard to the use of these net proceeds, and you
will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used in ways with which you
would agree. It is possible that the net proceeds will be invested in a way that does not yield us a favorable, or any, return. The failure
of our management to use the net proceeds effectively could have a material adverse effect on our business, financial condition, operating
results and cash flow.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investors in this offering will incur immediate
dilution from the public offering price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because the price per Ordinary
Share of the Ordinary Shares being offered is higher than the book value per share of the Ordinary Shares, you will suffer immediate dilution
in the net tangible book value of the Ordinary Shares you purchase in this offering. Assuming that an aggregate of 4,000,000 Ordinary
Shares are sold during the term of the Sales Agreement, at a price of $1.37 per Ordinary Share (the reported sale price of our Ordinary
Shares on the Nasdaq Capital Market on March 29, 2023), for aggregate gross proceeds of approximately $5,480,000, and after deducting
commissions and estimated offering expenses payable by us, you will experience immediate and substantial dilution of $0.20 per Ordinary
Share, with respect to the net tangible book value of the Ordinary Shares. See &ldquo;Dilution&rdquo; for a more detailed discussion of
the dilution you will incur in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The actual number of Ordinary Shares we will sell under the Sales
Agreement, as well as the price at which we may sell such Ordinary Shares, at any one time or in total, is uncertain.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to certain limitations
in the Sales Agreement, and compliance with applicable law, we have the discretion to deliver placement notices to Roth at any time throughout
the term of the Sales Agreement. The number of Ordinary Shares that are sold by Roth after delivering a placement notice will fluctuate
based on the market price of the Ordinary Shares during the sales period and limits, we set with Roth. In addition, the price at which
Ordinary Shares are sold by Roth, from time to time, will be dependent on the market price of our Ordinary Shares and, as a result, purchasers
of our Ordinary Shares that are sold under the Sales Agreement may purchase such Ordinary Shares at different prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A substantial number of our Ordinary Shares
may be sold in this offering and we may sell or issue additional Ordinary Shares in the future, which could cause the price of the Ordinary
Shares to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assuming we will sell an aggregate
of 4,000,000 Ordinary Shares during the term of the Sales Agreement with Roth, the underlying Ordinary Shares represented thereby will
equal approximately 34% of our outstanding Ordinary Shares as of March 28, 2023. &nbsp;This sale and any future issuances or sales of
a substantial number of Ordinary Shares or Ordinary Shares in the public market or otherwise, or the perception that such issuances or
sales may occur, could adversely affect the price of the Ordinary Shares. We have issued a substantial number of Ordinary Shares in connection
with the exercise of warrants and options to purchase our Ordinary Shares, and in the future we may issue additional shares in connection
with the exercise of existing warrants or options, which are eligible for, or may become eligible for, unrestricted resale. Any sales
or registration of such shares in the public market or otherwise could reduce the prevailing market price for the Ordinary Shares, as
well as make future sales of equity securities by us less attractive or not feasible, thus limiting our capital resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may need additional financing in the
future. We may be unable to obtain additional financing or if we obtain financing it may not be on terms favorable to us. You may lose
your entire investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our current plans,
we believe our existing cash and cash equivalents, along with cash generated from this offering, will be sufficient to fund our operating
expense and capital requirements for at least 12 months from the date of this prospectus supplement, although there is no assurance of
this and we may need additional funds in the future. If our capital resources are insufficient to meet future capital requirements, we
will have to raise additional funds. We may be unable to obtain additional funds through financing activities, and if we obtain financing
it may not be on terms favorable to us. If we are unable to obtain additional funds on terms favorable to us, we may be required to cease
or reduce our operating activities. If we must cease or reduce our operating activities, you may lose your entire investment.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The price of the Ordinary Shares may be
volatile.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of the Ordinary
Shares has fluctuated in the past. Consequently, the current market price of the Ordinary Shares may not be indicative of future market
prices, and we may be unable to sustain or increase the value of your investment in the Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have never paid cash dividends on our
share capital, and we do not anticipate paying any cash dividends in the foreseeable future.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends, and we do not anticipate paying cash dividends in the foreseeable future. Therefore, you should not rely on an investment
in Ordinary Shares as a source for any future dividend income.&nbsp;Our board of directors has complete discretion as to whether to distribute
dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any,
will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any,
received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board
of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ps_004"></A><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement,
the accompanying prospectus and certain information incorporated by reference in this prospectus supplement and the accompanying prospectus
contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act and Section 21E of the U.S. Securities
Exchange Act of 1934, as amended, or the Exchange Act, and other securities laws. Forward-looking statements are often characterized by
the use of forward-looking terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential&rdquo; &ldquo;intends&rdquo;
or &ldquo;continue,&rdquo; or the negative of these terms or other comparable terminology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements
that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements relating
to the research, development, completion and use of our products, and all statements (other than statements of historical facts) that
address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Forward-looking
statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements
on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current
conditions, expected future developments and other factors they believe to be appropriate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Important
factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking
statements include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our planned level of revenues and capital expenditures;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our available cash our ability to obtain additional funding;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our ability to market and sell our products;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our expectation regarding the sufficiency of our existing cash and cash equivalents to fund our current operations; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to advance the development of our products and future potential product candidates; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to commercialize our products and future potential product candidates and future sales of our products or any other future potential product candidates; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our assessment of the potential of our products and future potential product candidates to treat certain indications; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our planned level of capital expenditures and liquidity; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our plans to continue to invest in research and development to develop technology for new products; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to maintain our relationships with suppliers, manufacturers, distributors, and other partners;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">anticipated actions of the FDA, state regulators, if any, or other similar foreign regulatory agencies, including approval to conduct clinical trials, the timing and scope of those trials and the prospects for regulatory approval or clearance of, or other regulatory action with respect to our products or services; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the regulatory environment and changes in the health policies and regimes in the countries in which we intend to operate, including the impact of any changes in regulation and legislation that could affect the medical device industry; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to meet our expectations regarding the commercial supply of our products and future product candidates; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to retain key office holders; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to internally develop new inventions and intellectual property; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the overall global economic environment;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the impact of competition and new technologies;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">general market, political and economic conditions in the countries in which we operate;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the impact of competition and new technologies;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to internally develop new inventions and intellectual property;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">changes in our strategy; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">litigation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our
or our industry&rsquo;s actual results, levels of activity, performance or achievements to be materially different from those anticipated
by the forward-looking statements. We discuss many of these risks in this prospectus in greater detail under the heading &ldquo;Risk Factors&rdquo;
and elsewhere in this prospectus. You should not rely upon forward-looking statements as predictions of future events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking
statements, whether as a result of new information, future events or otherwise, after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ps_005"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue and sell our
Ordinary Shares having an aggregate sales price of up to $5,480,000 from time to time. Because there is no minimum offering amount required
as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable
at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the net proceeds
from the sale of securities under this prospectus for general corporate purposes, which include financing our operations, research and
development, including human observational studies, system engineering and other regulatory approval processes, business development marketing
activities and implementation of our commercialization strategy. The timing and amount of our actual expenditures will be based on many
factors, and we cannot specify with certainty all of the particular uses of the net proceeds from this offering. Accordingly, our management
will have significant discretion and flexibility in applying the net proceeds of this offering. We have no current commitments or binding
agreements with respect to any material acquisition of or investment in any technologies, products or companies.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pending our use of the net
proceeds from this offering, we may invest the net proceeds of this offering in a variety of capital preservation investments, including
but not limited to short-term, investment grade, interest bearing instruments and U.S. government securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ps_006"></A><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash
dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including
our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board
of directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law imposes
further restrictions on our ability to declare and pay dividends. Under the Companies Law, we may declare and pay dividends only if, upon
the determination of our board of directors, there is no reasonable concern that the distribution will prevent us from being able to meet
the terms of our existing and foreseeable obligations as they become due. Under the Companies Law, the distribution amount is further
limited to the greater of retained earnings or earnings generated over the two most recent years legally available for distribution according
to our then last reviewed or audited financial statements, provided that the end of the period to which the financial statements relate
is not more than six months prior to the date of distribution. In the event that we do not meet such earnings criteria, we may seek the
approval of a court in order to distribute a dividend. The court may approve our request if it is convinced that there is no reasonable
concern that the payment of a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ps_007"></A><B>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
our total liabilities and shareholders&rsquo; equity as of December 31, 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">on an actual basis; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">on a pro forma as adjusted basis to give additional effect to the sale
of 4,000,000 Ordinary Shares in this offering at an assumed public offering price of $1.37 per share, the reported sale price for our
Ordinary Shares as reported on the Nasdaq Capital Market on March 29, 2023, and after deducting commissions and estimated offering expenses
payable by us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
our capitalization and shareholders&rsquo; equity as of December 31, 2022 and should be read in conjunction with &ldquo;Use of Proceeds,&rdquo;
our financial statements and related notes that are incorporated by reference into this prospectus supplement and the accompanying prospectus
and the other financial information included or incorporated by reference into this prospectus supplement and the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The &ldquo;as adjusted&rdquo;
column below is illustrative only. Our as adjusted capitalization will depend on the actual purchase price and actual number of Ordinary
Shares represented sold under the Sales Agreement. You should read this table in conjunction with our audited financial statements and
related notes incorporated by reference in this prospectus supplement and the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S. dollars in thousands</I></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As of<BR>
December 31,<BR>
2022</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro Forma As Adjusted</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,783</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,969</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposits</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,120</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,120</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financials liability at Fair Value</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">368</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">368</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders&rsquo; equity (deficit):</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share capital and additional paid in capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,814</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign exchange reserve</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,928</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,928</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated deficit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total shareholders&rsquo; equity (deficit)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(39,064</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(44,250</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total capitalization</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,822</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,008</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of Ordinary Shares
purchased from us by existing shareholders is based on 11,700,103 Ordinary Shares issued and outstanding as of March 30, 2023, and excludes
the following as of such date:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">471,372 Ordinary Shares issuable upon the exercise of options to directors,
employees and consultants under our equity incentive plan, outstanding as of such date, with exercise prices ranging between NIS 0.37
(approximately $0.12) to NIS 0.97 (approximately $0.29) per share, and 29,400 Ordinary Shares issuable upon the exercise of options to
consultants under our equity incentive plan, outstanding as of such date, with exercise price of $3.08. 477,761 of the total options were
vested as of such date;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">1,391,056 RSUs granted to directors, employees, and consultants under our equity incentive plan, none of which were vested as of such date;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">36,550 Ordinary Shares reserved for future issuance under our equity incentive plan;&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">169,016 Ordinary Shares issuable upon the exercise of warrants issued to InSense Medical Pty Ltd. in connection with a certain termination agreement, with an exercise price of $5.50 per Ordinary Share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">795,832 Ordinary Shares issuable upon the exercise of warrants issued in connection with certain equity investment agreements, which we refer to as SAFEs&nbsp;and an additional 3,247 Ordinary Shares issuable upon the exercise of warrants issued to promoters in connection with such SAFEs; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">353,750 Ordinary Shares issuable upon the exercise of warrants issued in connection with a certain convertible loan, and an additional 13,340 Ordinary Shares issuable upon the exercise of warrants issued to promoters in connection with such convertible loan agreements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ps_008"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you invest in our Ordinary
Shares, you will experience immediate dilution to the extent of the difference between the public offering price of the Ordinary Shares
in this offering and the net tangible book value per Ordinary Share immediately after the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our net tangible book value
per Ordinary Share is determined by dividing our total tangible assets, less total liabilities, by the actual number of outstanding Ordinary
Shares. The net tangible book value of our Ordinary Shares as of December 31, 2022 was approximately $1.13 per share. Net tangible book
value per share represents the amount of our total tangible assets less our total liabilities, divided by 11,338,940, the total number
of Ordinary Shares outstanding at December 31, 2022.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After giving effect to the
sale of our Ordinary Shares during the term of the Sales Agreement with Roth in the aggregate amount of $5,480,000 at an assumed offering
price of $1.37 per Ordinary Share, the reported sale price of our Ordinary Shares on the Nasdaq Capital Market on March 29, 2023, and
after deducting commissions and estimated offering expenses payable by us, our <I>pro forma</I> as adjusted net tangible book value as
of December 31, 2022 would have been approximately $18 million, or $1.17 per share. This amount represents an immediate increase in net
tangible book value of $5,185,600 or $0.04 per Ordinary Share as a result of this offering and an immediate dilution of approximately
$0.20 per Ordinary Share to investors purchasing Ordinary Shares in this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table illustrates
this dilution on a per Ordinary Share basis. The as adjusted information is illustrative only and will adjust based on the actual prices
to the public, the actual number of Ordinary Shares sold, and other terms of the offering determined at the times our Ordinary Shares
are sold pursuant to this prospectus. The Ordinary Shares sold in this offering, if any, will be sold from time to time at various prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Public offering price per Ordinary Share</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.37</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Net tangible book value per Ordinary Share as of December 31, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"><FONT STYLE="font-size: 10pt">Increase in <I>pro forma</I> net tangible book value per Ordinary Share attributable to investors purchasing Ordinary Shares in this offering</FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.04</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><I>Pro forma</I> as adjusted net tangible book value per Ordinary Share after offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.17</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Dilution per Ordinary Share to investors purchasing Ordinary Shares in the offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.20</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The above discussion and table
are based on 11,338,940 Ordinary Shares outstanding as of December 31, 2022. To the extent that outstanding options or warrants are exercised,
or we issue additional Ordinary Shares under our incentive equity plan, you may experience further dilution. In addition, we may choose
to raise additional capital due to market conditions or strategic considerations even if we believe that we have sufficient funds for
our current and future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt
securities, the issuance of those securities could result in further dilution to the holders of our Ordinary Shares and the Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ps_009"></A><B>PLAN OF DISTRIBUTION</B><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into the Sales
Agreement with Roth under which we may issue and sell Ordinary Shares from time to time in an amount up to $5,480,000 through or to Roth,
acting as sales agent or principal. Sales of our Ordinary Shares, if any, under this prospectus supplement will be made at market prices
by any method deemed to be an &ldquo;at the market offering&rdquo; as defined in Rule 415(a)(4) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.5pt">Each time that we wish to
issue and sell our Ordinary Shares under the Sales Agreement, we will provide Roth with a placement notice describing the amount of Ordinary
Shares to be sold, the time period during which sales are requested to be made, any limitation on the amount of Ordinary Shares that may
be sold in any single day, any minimum price below which sales may not be made or any minimum price requested for sales in a given time
period and any other instructions relevant to such requested sales. Upon receipt of a placement notice, Roth, acting as our sales agent,
will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal laws,
rules and regulations and the rules of the Nasdaq Capital Market, to sell our Ordinary Shares under the terms and subject to the conditions
of the placement notice and the Sales Agreement. We or Roth may suspend the offering of Ordinary Shares pursuant to a placement notice
upon notice and subject to other conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.5pt">Unless the parties agree
otherwise, settlement for sales of Ordinary Shares will occur on the second trading day following the date on which any sales are made
in return for payment of the net proceeds to us. There are no arrangements to place any of the proceeds of this offering in an escrow,
trust or similar account. Sales of our Ordinary Shares as contemplated in this prospectus supplement will be settled through the facilities
of The Depository Trust Company or by such other means as we and Roth may agree upon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.5pt">We will pay Roth commissions
for its services in acting as our sales agent in the sale of our Ordinary Shares pursuant to the Sales Agreement. Roth will be entitled
to compensation at a fixed commission rate of 3.0%&nbsp;of the gross proceeds from the sale of our Ordinary Shares on our behalf pursuant
to the Sales Agreement. We have agreed to reimburse Roth for its reasonable and documented out-of-pocket expenses (including but not limited
to the reasonable and documented fees and expenses of its legal counsel) in an amount not to exceed $40,000 and for Roth&rsquo;s reasonable
and documented out-of-pocket expenses related to quarterly maintenance of the Sales Agreement (including but not limited to the reasonable
and documented fees and expenses of its legal counsel) on a quarterly basis in an amount not to exceed $5,000. We have also agreed to
pay Roth advisory fees upon execution of our engagement letter an amount of $50,000.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.5pt">We estimate that the total
expenses for this offering, excluding compensation payable to Roth and certain expenses reimbursable to Roth under the terms of the Sales
Agreement, will be approximately $20,000. The remaining sales proceeds, after deducting any expenses payable by us and any transaction
fees imposed by any governmental, regulatory, or self-regulatory organization in connection with the sales, will equal our net proceeds
for the sale of such Ordinary Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Because
there are no minimum sale requirements as a condition to this offering, the actual total public offering price, commissions and net proceeds
to us, if any, are not determinable at this time. The actual dollar amount and number of Ordinary Shares we sell through this prospectus
supplement will be dependent, among other things, on market conditions and our capital raising requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
connection with the sale of the Ordinary Shares on our behalf, Roth will be deemed to be an &ldquo;underwriter&rdquo; within the meaning
of the Securities Act, and the compensation of Roth will be deemed to be underwriting commissions or discounts. We have agreed to provide
indemnification and contribution to Roth against certain civil liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Roth
will not engage in any market making activities involving our Ordinary Shares while the offering is ongoing under this prospectus supplement
if such activity would be prohibited under Regulation M or other anti-manipulation rules under the Securities Act. As our sales agent,
Roth will not engage in any transactions that stabilizes our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The offering
pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all Ordinary Shares subject to the Sales Agreement
and (ii) termination of the Sales Agreement as permitted therein. We may terminate the Sales Agreement in our sole discretion at any time
by giving five days&rsquo; prior notice to Roth. Roth may terminate the Sales Agreement under the circumstances specified in the Sales
Agreement and in its sole discretion at any time by giving five days&rsquo; prior notice to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Sales Agreement has been filed as an exhibit to a Report of Foreign Private Issuer on Form 6-K that we filed with the SEC in connection
with this offering and is incorporated into this prospectus supplement by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Roth
and/or its affiliates have provided, and may in the future provide, various investment banking and other financial services for us, for
which services they have received and may in the future receive customary fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
prospectus supplement in electronic format may be made available on a website maintained by Roth, and Roth may distribute this prospectus
supplement electronically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Foreign Regulatory Restrictions on Purchase
of Securities Offered Hereby Generally</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No action has been or will
be taken in any jurisdiction (except in the United States) that would permit a public offering of the securities offered by this prospectus
supplement and accompanying prospectus, or the possession, circulation or distribution of this prospectus supplement and accompanying
prospectus or any other material relating to us or the securities offered hereby in any jurisdiction where action for that purpose is
required. Accordingly, the securities offered hereby may not be offered or sold, directly or indirectly, and neither of this prospectus
supplement and accompanying prospectus nor any other offering material or advertisements in connection with the securities offered hereby
may be distributed or published, in or from any country or jurisdiction except in compliance with any applicable rules and regulations
of any such country or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ps_010"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain legal matters concerning
this offering will be passed upon for us by Sullivan &amp; Worcester LLP, New York, New York. Certain legal matters with respect to the
legality of the issuance of the securities offered by this prospectus and other legal matters concerning this offering relating to Israeli
law will be passed upon for us by Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), Tel Aviv, Israel.&nbsp;&nbsp;Duane Morris, LLP
is acting as counsel to Roth.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ps_011"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements as
of December 31, 2022 and 2021 and for each of the three years in the period ended December 31, 2022, incorporated by reference into this
prospectus and in the registration statement have been so incorporated in reliance on the report of Ziv Haft, a member firm of BDO, an
independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing
and accounting.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ps_012"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement
and the accompanying prospectus are part of a registration statement on Form F-3 filed by us with the SEC under the Securities Act. As
permitted by the rules and regulations of the SEC, this prospectus supplement and the accompanying prospectus do not contain all the information
set forth in the registration statement and the exhibits thereto filed with the SEC. For further information with respect to us and the
Ordinary Shares offered hereby, you should refer to the complete registration statement on Form F-3, which may be obtained from the locations
described above in the immediately preceding paragraph. Statements contained in this prospectus supplement, the accompanying prospectus
supplement or any document incorporated by reference herein or therein about the contents of any contract or other document are not necessarily
complete. If we have filed any contract or other document as an exhibit to the registration statement or any other document incorporated
by reference in the registration statement, you should read the exhibit for a more complete understanding of the document or matter involved.
Each statement regarding a contract or other document is qualified in its entirety by reference to the actual document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may read and copy the
registration statement, including the related exhibits and schedules, and any document we file with the SEC without charge at the SEC&rsquo;s
public reference room at 100&nbsp;F Street, N.E., Room&nbsp;1580, Washington, DC 20549. You may also obtain copies of the documents at
prescribed rates by writing to the Public Reference Section of the SEC at 100&nbsp;F Street, N.E., Room&nbsp;1580, Washington, DC 20549.
Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also maintains an Internet website
that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are also
available to the public through the SEC&rsquo;s website at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements are filing reports
with the SEC. Those other reports or other information may be inspected without charge at the locations described above. As a foreign
private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our
officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16
of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial
statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However,
we are required to file with the SEC, within 120&nbsp;days after the end of each fiscal year, or such applicable time as required by the
SEC, an annual report on Form&nbsp;20-F containing financial statements audited by an independent registered public accounting firm, and
will submit to the SEC, on Form&nbsp;6-K, unaudited interim financial information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
at www.inspira-technologies.com. Information contained on, or that can be accessed through, our website does not constitute a part of
this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. We will post on our
website any materials required to be so posted on such website under applicable corporate or securities laws and regulations, including,
posting any XBRL interactive financial data required to be filed with the SEC and any notices of general meetings of our shareholders.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><A NAME="ps_013"></A><B>INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate
by reference&rdquo; the information we file with it, which means that we can disclose important information to you by referring you to
those documents. The information incorporated by reference is considered to be part of this prospectus and information we file later with
the SEC will automatically update and supersede this information. The information incorporated by reference is considered to be part of
this prospectus and information we file later with the SEC will automatically update and supersede this information. The following documents
filed with or furnished to the SEC by us are incorporated by reference in this prospectus supplement and the accompanying prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">Our Annual Report on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390023025412/f20f2022_inspiratech.htm">Form 20-F</A>&nbsp;for the fiscal year ended December 31, 2022, filed with the SEC on March 31, 2023;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our Reports on Form 6-K furnished on January 23, 2023 (with respect
    to the first four and the sixth and seventh paragraphs, and the section titled &ldquo;Forward-Looking Statements&rdquo;), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390023008263/ea172783-6k_inspiratech.htm">February
    6, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390023010522/ea173329-6k_inspiratech.htm">February 13,
    2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390023022073/f6k032223_inspiratech.htm">March 22,
    2023</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390023026743/ea176446-6k_inspiratech.htm">April
    4, 2023</A> (with respect to the first paragraph, the sections titled &ldquo;Financial results for the twelve months ended December
    31, 2022,&rdquo; &ldquo;Financial results for the three months ended December 31, 2022,&rdquo; &ldquo;Balance Sheet Highlights,&rdquo;
    &ldquo;Forward-Looking Statements&rdquo; and the financial statements); and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The description of our securities contained in&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390023025412/f20f2022ex2-1_inspiratech.htm">Exhibit 2.1</A>&nbsp;to our Annual Report on Form 20-F for the fiscal year ended December 31, 2022, filed with the SEC on March 31, 2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All subsequent Annual Reports
filed by us pursuant to the Exchange Act on Form 20-F prior to the termination of this offering shall be deemed to be incorporated by
reference to this prospectus supplement and the accompanying prospectus and to be a part hereof and thereof from the date of filing of
such documents. We may also incorporate any Form 6-K subsequently submitted by us to the SEC prior to the termination of this offering
by identifying in such Forms 6-K that they are being incorporated by reference herein and in the accompanying prospectus, and any Forms
6-K so identified shall be deemed to be incorporated by reference in this prospectus supplement and the accompanying prospectus and to
be a part hereof from the date of submission of such documents. Any statement contained in a document incorporated or deemed to be incorporated
by reference herein and in the accompanying prospectus shall be deemed to be modified or superseded for purposes of this prospectus supplement
and the accompanying prospectus to the extent that a statement contained herein or in any other subsequently filed document which also
is incorporated or deemed to be incorporated by reference herein and in the accompanying prospectus modifies or supersedes such statement.
Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus
supplement or the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information we incorporate
by reference is an important part of this prospectus supplement and the accompanying prospectus, and later information that we file with
the SEC that is incorporated by reference will automatically update and supersede the information contained in this prospectus supplement
and the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will provide you without
charge, upon your written or oral request, a copy of any of the documents incorporated by reference in this prospectus, other than exhibits
to such documents which are not specifically incorporated by reference into such documents. Please direct your written or telephone requests
to us at 2 Ha-Tidhar St., Ra&rsquo;anana, 4366504 Israel, Tel: +972-996-64488; Attention: Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$50,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Inspira Technologies Oxy B.H.N. Ltd. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may offer and sell from
time to time in one or more offerings up to the total amount of $50,000,000 of our ordinary shares, no par value, or the Ordinary Shares,
warrants or units comprising a combination of Ordinary Shares and warrants. We refer to the Ordinary Shares, the Warrants, and the Ordinary
Shares issued or issuable upon exercise of the Warrants, collectively, as the securities. Each time we sell securities pursuant to this
prospectus, we will provide in a supplement to this prospectus the price and any other material terms of any such offering. We may also
authorize one or more free writing prospectuses to be provided to you in connection with each offering. Any prospectus supplement and
related free writing prospectuses may also add, update or change information contained in the prospectus. You should read this prospectus,
any applicable prospectus supplement and related free writing prospectuses, as well as the documents incorporated by reference or deemed
incorporated by reference into this prospectus, carefully before you invest in the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares
and IPO Warrants are listed on the Nasdaq Capital Market, or Nasdaq, under the symbols &ldquo;IINN&rdquo; and &ldquo;IINNW,&rdquo; respectively.
On August 1, 2022, the last reported sale price of our Ordinary Shares and IPO Warrants on Nasdaq was $1.77 per share and $0.2201 per
warrant, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 1, 2022, the aggregate
market value of our Ordinary Shares held by non-affiliates was approximately $14,900,000, based on 8,433,976 Ordinary Shares outstanding
and a per share price of $1.77 based on the closing sale price of our Ordinary Shares on July 29, 2022. We have not offered any securities
pursuant to General Instruction I.B.5 on Form F-3 during the prior 12 calendar month period that ends on and includes the date of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an emerging growth
company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and are subject to reduced public company reporting
requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investing in the securities
involves a high degree of risk. Risks associated with an investment in the securities will be described in any applicable prospectus supplement
and are and will be described in certain of our filings with the Securities and Exchange Commission, or SEC, as described in &ldquo;Risk
Factors&rdquo; beginning on page 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The securities may be sold
directly by us to investors, through agents designated from time to time or to or through underwriters or dealers, or through a combination
of such methods, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section
entitled &ldquo;Plan of Distribution&rdquo; in this prospectus. If any agents or underwriters are involved in the sale of the securities
with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions,
discounts and over-allotment options will be set forth in a prospectus supplement. The price to the public of the securities and the net
proceeds that we expect to receive from such sale will also be set forth in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the SEC nor any
state or other securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The date of this prospectus is August 18, 2022 </B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TABLE
OF CONTENTS</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 93%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">About this Prospectus</A></FONT></TD>
    <TD STYLE="width: 7%; text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">About Our Company</A></FONT></TD>
    <TD STYLE="text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">Risk Factors</A></FONT></TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">Cautionary Note Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">Capitalization</A></FONT></TD>
    <TD STYLE="text-align: center">4</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">Use of Proceeds</A></FONT></TD>
    <TD STYLE="text-align: center">5</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">Description of Securities</A> </FONT></TD>
    <TD STYLE="text-align: center">6</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">Plan of Distribution</A></FONT></TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">Legal Matters</A></FONT></TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">Experts</A></FONT></TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Expenses</A></FONT></TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">Incorporation of Certain Information by Reference</A></FONT></TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">Where You Can Find More Information</A> </FONT></TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">Enforceability of Civil Liabilities</A></FONT></TD>
    <TD STYLE="text-align: center">14</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 20; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<DIV STYLE="border: Black 1.5pt solid; padding: 5pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is part of
a registration statement on Form F-3 that we filed with the SEC utilizing a &ldquo;shelf&rdquo; registration process. Under this shelf
registration process, we may offer from time to time up to an aggregate of $50,000,000 of the Ordinary Shares, warrants or units comprising
a combination of Ordinary Shares and warrants in one or more offerings. We sometimes refer to the Ordinary Shares, warrants and units
as the &ldquo;securities&rdquo; throughout this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each time we sell securities,
we will provide you with a prospectus supplement that will describe the specific amounts, prices and terms of such offering. We may also
authorize one or more free writing prospectuses to be provided to you in connection with such offering. The prospectus supplement and
any related free writing prospectuses may also add, update or change information contained in this prospectus. You should read carefully
both this prospectus, the applicable prospectus supplement, the documents incorporated by reference into this prospectus and any related
free writing prospectus together with additional information described below under &ldquo;Where You Can Find More Information&rdquo; and
&ldquo;Incorporation of Certain Information by Reference&rdquo; before buying the securities being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus does not contain
all of the information provided in the registration statement that we filed with the SEC. For further information about us or the securities,
you should refer to that registration statement, which you can obtain from the SEC as described below under &ldquo;Where You Can Find
More Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only on the
information contained or incorporated by reference in this prospectus, a prospectus supplement and related free writing prospectuses.
Neither we, nor any agent, underwriter or dealer has authorized any other person to provide you with different information. If anyone
provides you with different or inconsistent information, you should not rely on it. This prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. You should not
assume that the information contained in this prospectus and the accompanying prospectus supplement or related free writing prospectuses
is accurate on any date subsequent to the date set forth on the front of the document or that any information that we have incorporated
by reference is correct on any date subsequent to the date of the document incorporated by reference. Our business, financial condition,
results of operations and prospects may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
this prospectus, &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company&rdquo; and &ldquo;Inspira&rdquo; refer to Inspira
Technologies Oxy B.H.N. Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">All
trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks
and trade names in this prospectus are referred to without the &reg; and &trade; symbols, but such references should not be construed
as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do
not intend the use or display of other companies&rsquo; trademarks and trade names to imply a relationship with, or endorsement or sponsorship
of us by, any other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
reporting currency is the U.S. dollar and our functional currency is New Israeli Shekels.&nbsp;Unless otherwise expressly stated or the
context otherwise requires, references in this prospectus to &ldquo;NIS&rdquo; are to New Israeli Shekels, references to A$ are to Australian
dollars, and references to &ldquo;dollars&rdquo; or &ldquo;$&rdquo; are to U.S. dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
prospectus includes statistical, market and industry data and forecasts which we obtained from publicly available information and independent
industry publications and reports that we believe to be reliable sources. These publicly available industry publications and reports generally
state that they obtain their information from sources that they believe to be reliable, but they do not guarantee the accuracy or completeness
of the information. Although we believe that these sources are reliable, we have not independently verified the information contained
in such publications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
report under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or the IASB.&nbsp;None
of the financial statements were prepared in accordance with generally accepted accounting principles in the United States.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Options: NewSection -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="border: Black 1.5pt solid; padding: 5pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>ABOUT OUR COMPANY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a groundbreaking respiratory
support technology company in the medical device industry engaged in the research, development, manufacturing related activities, and
go to market activities of proprietary products and technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing the following
products:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><U>The INSPIRA ART Device</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART device (previously/also
known as the ART500 or ART), described herein as the &ldquo;INSPIRA ART,&rdquo; &ldquo;INSPIRA ART device&rdquo; or &ldquo;INSPIRA ART
system.&rdquo; The INSPIRA ART (Augmented Respiratory Technology) is a respiratory support technology targeting to utilize direct blood
oxygenation to boost patient saturation levels within minutes while the patient is awake &amp; spontaneously breathing. The aim is to
reduce the need for invasive mechanical ventilation, or IMV, with the potential to reduce risks, complications and high costs and potentially
allowing for larger patient populations in and beyond ICU settings. The INSPIRA ART is being designed as a new intent of use for long-term
(longer than 6 hours) respiratory support that provides assisted extracorporeal circulation and physiologic gas exchange (oxygenation
and CO2 removal) of the patient&rsquo;s blood in adults with acute respiratory failure, targeting to allow for treatment of patients while
they are awake. The INSPIRA ART is being designed to potentially prevent the need for invasive mechanical ventilation, targeting acute
respiratory failure patients in intensive care units, or ICUs, and general medical units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><U>The HYLA Blood Sensor</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HYLA blood sensor is a
non-invasive optical blood sensor designed to perform real-time and continuous blood measurements, potentially minimizing the need to
take actual blood samples from patients. The HYLA&rsquo;s measurement can assist physicians in the monitoring of patient&rsquo;s clinical
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HYLA blood sensor is being
designed as a clip-on sensor, attached to the outer walls of a blood tube, that may potentially reduce risks, complications, and costs.
The HYLA blood sensor may have broad application potential, benefiting patients undergoing procedures such as cardiopulmonary bypass operations,
Extracorporeal Membrane Oxygenation, or ECMO, Dialysis and Cardiopulmonary bypass, pending regulatory approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><U>The Alice System</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Alice System,
described herein as the &ldquo;Alice,&rdquo; or the &ldquo;Alice system,&rdquo; an advanced form of life support system better known
by the medical industry as a cardiopulmonary bypass system, or &ldquo;CPB,&rdquo; is being designed for use for surgical procedures
requiring cardiopulmonary bypass for 6 hours or less.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Alice system is expected to be submitted to the U.S. Food and Drug
Administration, or FDA, for 510k clearance, during the second half of 2023. The Alice is designed to be a new generation CPB, system
with potential advantages to medical device design, including a large touchscreen and novel colorful graphical representation that
increases the visibility and functionality of data displayed to the medical staff. The Alice system is being designed with a rapid
style aerospace-grade aluminum structure to be both lightweight and highly durable and will be equipped with long battery life. The
Alice system, designed as a CPB, shall be indicated for use for surgical procedures requiring cardiopulmonary bypass for 6 hours or
less, was referred to previously as the Liby or ECLS system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a goal to set a new
standard of care in various areas of patient care. As part of our strategy to reach these goals, and in parallel to pursuing regulatory
approvals, we are actively working to establish collaborations with strategic partners and globally ranked health center to provide endorsement
and clinical adoption for regional deployments of our respiratory support, heart-lung bypass, ECMO and blood monitoring products and technologies.
We plan to target ICUs, general medical units, Operating theaters, emergency medical services and small urban and rural hospitals, with
the goal of making our solutions more accessible to millions of patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are an Israeli corporation based in Ra&rsquo;anana, Israel and were incorporated in Israel in 2018 under the name Clearx Medical Ltd.
On April 10, 2018, our name was changed to Insense Medical Ltd. and on July 30, 2020, our name was changed to our current name, Inspira
Technologies Oxy B.H.N. Ltd. Our principal executive offices are located at 2 Ha-Tidhar St., Ra&rsquo;anana, 4366504 Israel. Our telephone
number in Israel is 972 996 644 88. Our website address is <I>www.inspira-technologies.com</I>. The information contained on, or that
can be accessed through, our website is not part of this prospectus. We have included our website address in this prospectus solely as
an inactive textual reference. Our Ordinary Shares and IPO Warrants are listed on the Nasdaq Capital Market, or Nasdaq, under the symbols
&ldquo;IINN&rdquo; and &ldquo;IINNW,&rdquo; respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_003"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Investing in our securities
involves risks. Please carefully consider the risk factors described in our periodic reports filed with the SEC, including those set forth
under the caption &ldquo;Item 3. Key Information - D. Risk Factors&rdquo; in our most recent Annual Report on Form 20-F for the year ended
December 31, 2021, or the 2021 Annual Report, or any updates in our Reports on Form 6-K, which are incorporated by reference in this prospectus,
together with all of the other information appearing in this prospectus or incorporated by reference into this prospectus and any applicable
prospectus supplement, in light of your particular investment objectives and financial circumstances. Additional risks and uncertainties
not currently known to us or that we currently deem to be immaterial may also impair our business operations. If any of these risks actually
occur, our business, financial condition, operating results or cash flows could be materially adversely affected. This could cause the
trading price of our securities to decline, and you may lose all or part of your investment. The discussion of risks includes or refers
to forward-looking statements; you should read the explanation of the qualifications and limitations on such forward-looking statements
discussed elsewhere in this prospectus. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus contains,
and any accompanying prospectus supplement will contain, forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act,
and the Private Securities Litigation Reform Act of 1995. Also, documents that we incorporate by reference into this prospectus, including
documents that we subsequently file with the SEC, contain and will contain forward-looking statements. Forward-looking statements are
those that predict or describe future events or trends and that do not relate solely to historical matters. You can generally identify
forward-looking statements as statements containing the words &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate&rdquo; &ldquo;objective,&rdquo; &ldquo;goal,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;project,&rdquo; &ldquo;plan,&rdquo; &ldquo;assume&rdquo; or other similar expressions, or negatives of those
expressions, although not all forward-looking statements contain these identifying words. All statements contained or incorporated by
reference in this prospectus and any prospectus supplement regarding our objectives, plans and strategies, statements that contain projections
of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development,
completion and use of our products, and all statements (other than statements of historical facts) that address activities, events or
developments that we intend, expect, project, believe or anticipate will or may occur in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should not place undue
reliance on our forward-looking statements because the matters they describe are subject to certain risks, uncertainties and assumptions,
including in many cases decisions or actions by third parties, that are difficult to predict. Our forward-looking statements are based
on the information currently available to us and speak only as of the date on the cover of this prospectus, the date of any prospectus
supplement, or, in the case of forward-looking statements incorporated by reference, the date of the filing that includes the statement.
Over time, our actual results, performance or achievements may differ from those expressed or implied by our forward-looking statements,
and such difference might be significant and materially adverse to our security holders. We undertake no obligation to update publicly
any forward-looking statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have identified some of
the important factors that could cause future events to differ from our current expectations and they are described in this prospectus
and supplements to this prospectus (if any) under the caption &ldquo;Risk Factors,&rdquo; &ldquo;Use of Proceeds,&rdquo; and elsewhere
in this prospectus, as well as in our most recent Annual Report on Form 20-F, including without limitation under the captions &ldquo;Risk
Factors&rdquo; and &ldquo;Operating and Financial Review and Prospects,&rdquo; and in other documents that we may file with the SEC,
all of which you should review carefully. Please consider our forward-looking statements in light of those risks as you read this prospectus,
the documents incorporated by reference herein, and any prospectus supplement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_005"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
our cash and cash equivalents and our capitalization as of December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read this table
in conjunction with the section titled &ldquo;Item 5. Operating and Financial Review and Prospects&rdquo; and our financial statements
and related notes included in our 2021 Annual Report on Form 20-F, incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; font-style: italic">U.S. dollars in thousands</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<BR> December&nbsp;31,<BR> 2021</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">23,749</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Financials liability at Fair Value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,215</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shareholders&rsquo; equity (deficit):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Share capital and additional paid in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,935</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Foreign exchange reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">210</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,791</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total shareholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,354</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total capitalization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,870</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>USE OF PROCEEDS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Unless
otherwise indicated in an accompanying prospectus supplement, we intend to use the net proceeds from the sale of our securities in this
offering for&nbsp;product integration, research and development, including human observational studies, system engineering and other regulatory
approval process, business development and marketing activities and implementation of our go-to-market strategy, and working capital and
general corporate purposes and next generation product development. However, we have no present binding commitments or agreements to enter
into any acquisitions. The amounts and timing of our actual expenditures will depend upon numerous factors, including the progress of
our development and commercialization efforts, whether or not we enter into strategic collaborations or partnerships, and our operating
costs and expenditures. Accordingly, our management will have significant flexibility in applying the net proceeds of this offering. Pending
application of the net proceeds for the purposes as described above, we may invest the net proceeds in short-term, interest-bearing securities,
and U.S. government securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>DESCRIPTION OF SECURITIES</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
descriptions of the securities contained in this prospectus, together with the applicable prospectus supplements, summarize the material
terms and provisions of the various types of securities that we may offer. We will describe in the applicable prospectus supplement relating
to any securities the particular terms of the securities offered by that prospectus supplement. If we so indicate in the applicable prospectus
supplement, the terms of the securities may differ from the terms we have summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
may sell from time to time, in one or more offerings, Ordinary Shares, warrants to purchase Ordinary Shares or units comprising a combination
of Ordinary Shares and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this prospectus, we refer
to the Ordinary Shares and warrants to purchase Ordinary Shares and units that may be offered by us collectively as &ldquo;securities.&rdquo;
The total dollar amount of all securities that we may issue under this prospectus will not exceed $50,000,000. The actual price per share
of the shares that we will offer, or per security of the securities that we will offer, pursuant hereto will depend on a number of factors
that may be relevant as of the time of offer. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus may not be
used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue warrants independently
or together with any other securities offered by any prospectus supplement and the warrants may be attached to or separate from those
securities. We will evidence each series of warrants by warrant certificates that we may issue under a separate agreement or other evidence.
Any series of warrants may be issued under a separate warrant agreement, which may be entered into between us and a warrant agent specified
in an applicable prospectus supplement relating to a particular series of warrants. Any such warrant agent will act solely as our agent
in connection with the warrants of such series and will not assume any obligation or relationship of agency or trust with any of the holders
of the warrants. We may also choose to act as our own warrant agent. We will set forth further terms of the warrants and any applicable
warrant agreements in the applicable prospectus supplement relating to the issuance of any warrants, including, where applicable, the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the title of the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the aggregate number of the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exchange distributions and/or secondary distributions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of securities purchasable upon exercise of the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation and terms of the securities, if any, with which the warrants are issued, and the number of the warrants issued with each such offered security;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date, if any, on and after which the warrants and the related securities will be separately transferable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the price at which, and form of consideration for which, each security purchasable upon exercise of the warrants may be purchased;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which the right to exercise the warrants will commence and the date on which the right will expire;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if applicable, the date on and after which such warrants and the related securities will be separately transferable;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the manner in which the warrants may be exercised, which may include by cashless exercise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of any rights to redeem or call the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any provisions for changes to or adjustments in the exercise price or number of Ordinary Shares issuable upon exercise of the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information with respect to book-entry procedures, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if applicable, a discussion of the material Cayman Island and U.S. income tax considerations applicable to the issuance or exercise of such warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the anti-dilution and adjustment of share capital provisions of the warrants, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the minimum or maximum amount of the warrants which may be exercised at any one time;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any circumstances that will cause the warrants to be deemed to be automatically exercised; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other material terms of the warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue units comprised
of one or more of the other securities that may be offered under this prospectus, in any combination. As specified in the applicable prospectus
supplement, we may issue units consisting of our Ordinary Shares, warrants or any combination of such securities. Each unit will be issued
so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights
and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities
included in the unit may not be held or transferred separately at any time, or at any time before a specified date. The applicable prospectus
supplement will describe:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of the units and of the Ordinary Shares and/or warrants comprising the units, including whether and under what circumstances the securities comprising the units may be traded separately;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a description of the terms of any unit agreement governing the units or any arrangement with an agent that may act on our behalf in connection with the unit offering;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a description of the provisions for the payment, settlement, transfer or exchange of the units; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any material provisions of the governing unit agreement that differ from those described above.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The description in the applicable
prospectus supplement of any units we offer will not necessarily be complete and will be qualified in its entirety by reference to the
applicable unit agreement, which will be filed with the SEC if we offer units. For more information on how you can obtain copies of the
applicable unit agreement if we offer units, see &ldquo;Where You Can Find Additional Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
being offered hereby in one or more of the following methods from time to time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;<FONT STYLE="font-family: Symbol"></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a block trade (which may involve crosses) in
which the broker or dealer so engaged will attempt to sell the securities as agent but may position and resell a portion of the block
as principal to facilitate the transaction;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">purchases by a broker or dealer as principal
and resale by such broker or dealer for its own account pursuant to this prospectus;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">exchange distributions and/or secondary distributions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ordinary brokerage transactions and transactions
in which the broker solicits purchasers;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to one or more underwriters for resale to the
public or to investors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">through agents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">in an &ldquo;at the market offering,&rdquo; within
the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or
otherwise;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">directly to a purchaser pursuant to what is known
as an &ldquo;equity line of credit&rdquo; as described below;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">transactions not involving market makers or established
trading markets, including direct sales or privately negotiated transactions; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">through a combination of these methods of sale.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The securities that we distribute by any of these
methods may be sold, in one or more transactions, at:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a fixed price or prices, which may be changed;
</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">market prices prevailing at the time of sale;
</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">prices related to prevailing market prices; or
</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">negotiated prices.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will set forth in a prospectus
supplement the terms of the offering of securities, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the name or names of any agents, dealers or underwriters;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the purchase price of the securities being offered
and the proceeds we will receive from the sale; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any over-allotment options under which underwriters
may purchase additional securities from us; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any agency fees or underwriting discounts and
other items constituting agents&rsquo; or underwriters&rsquo; compensation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the public offering price;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any discounts or concessions allowed or re-allowed
or paid to dealers; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any securities exchanges or markets on which
such securities may be listed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If underwriters are used in
the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions
at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase
the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the
public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain
conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities
covered by any over-allotment option. Any public offering price and any discounts or concessions allowed or re-allowed or paid to dealers
may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement,
naming the underwriter, the nature of any such relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell securities directly
or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe
any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will
act on a best-efforts basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also sell securities
directly to one or more purchasers without using underwriters or agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Underwriters, dealers and
agents that participate in the distribution of the securities may be underwriters as defined in the Securities Act and any discounts or
commissions they receive from us and any profit on their resale of the securities may be treated as underwriting discounts and commissions
under the Securities Act. We will identify in the applicable prospectus supplement any underwriters, dealers or agents and will describe
their compensation. We may have agreements with the underwriters, dealers and agents to indemnify them against specified civil liabilities,
including liabilities under the Securities Act. Underwriters, dealers and agents may engage in transactions with or perform services for
us in the ordinary course of their businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with an offering,
an underwriter may purchase and sell securities in the open market. These transactions may include short sales, stabilizing transactions
and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of securities
than they are required to purchase in the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, to cover these
short sales positions or to otherwise stabilize or maintain the price of the securities, the underwriters may bid for or purchase securities
in the open market and may impose penalty bids. If penalty bids are imposed, selling concessions allowed to syndicate members or other
broker-dealers participating in the offering are reclaimed if securities previously distributed in the offering are repurchased, whether
in connection with stabilization transactions or otherwise. The effect of these transactions may be to stabilize or maintain the market
price of the securities at a level above that which might otherwise prevail in the open market. The impositions of a penalty bid may also
affect the price of the securities to the extent that it discourages resale of the securities. The magnitude or effect of any stabilization
or other transactions is uncertain. These transactions may be effected on The Nasdaq Capital Market or otherwise and, if commenced, may
be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>EXPENSES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are paying all of the expenses
of the registration of our securities under the Securities Act, including, to the extent applicable, registration and filing fees, printing
fees and expenses, accounting fees and the legal fees of our counsel. We estimate these expenses to be approximately $20,635 which at
the present time include the following categories of expenses:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,635</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Printer fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Accounting fees and expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">20,635</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we anticipate incurring additional expenses in the future
in connection with the offering of our securities pursuant to this prospectus. Any such additional expenses will be disclosed in a prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain legal matters concerning
this offering will be passed upon for us by Sullivan &amp; Worcester LLP, New York, New York. Certain legal matters with respect to the
legality of the issuance of the securities offered by this prospectus and other legal matters concerning this offering relating to Israeli
law will be passed upon for us by Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), Tel Aviv, Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements as of December 31, 2021, and 2020and for each
of the three years in the period ended December 31, 2021, incorporated by reference into this prospectus and in the Registration Statement
have been so included in reliance on the report of Ziv Haft, a member firm of BDO, an independent registered public accounting firm, incorporated
herein by reference given on the authority of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_012"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate
by reference&rdquo; the information we file with it, which means that we can disclose important information to you by referring you to
those documents. The information incorporated by reference is considered to be part of this prospectus and information we file later with
the SEC will automatically update and supersede this information. The information incorporated by reference is considered to be part of
this prospectus and information we file later with the SEC will automatically update and supersede this information. The documents we
are incorporating by reference as of their respective dates of filing are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Annual Report on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1837493/000121390022016867/f20f2021_inspiratech.htm">Form 20-F</A> for the fiscal year ended December 31, 2021, filed with the SEC on March 31, 2022; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">Our Reports on Form 6-K submitted on <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390022000848/ea153622ex99-1inspiratech.htm">January
6, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390022002664/ea154178ex99-1_inspira.htm">January 19, 2022</A>
(with respect to the first five paragraphs and the section titled &ldquo;Forward-Looking Statement Disclaimer&rdquo; in the press release
attached as Exhibit 99.1 to the Form 6-K), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390022004130/ea154573ex99-1_inspiratech.htm">January
28, 2022</A> (with respect to the first two paragraphs and the section titled &ldquo;Forward-Looking Statement Disclaimer&rdquo; in the
press release attached as Exhibit 99.1 to the Form 6-K), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390022004379/ea154686ex99-1_inspiratech.htm">January
31, 2022</A> (with respect to the first four paragraphs and the section titled &ldquo;Forward-Looking Statement Disclaimer&rdquo; in the
press release attached as Exhibit 99.1 to the Form 6-K), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390022004685/ea154780ex99-1_inspira.htm">February
1, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390022005160/ea154901ex99-1_inspira.htm">February 3, 2022</A>
(with respect to the first four paragraphs and the section titled &ldquo;Forward-Looking Statement Disclaimer&rdquo; in the press release
attached as Exhibit 99.1 to the Form 6-K), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390022016744/ea157733ex99-1_inspira.htm">March
31, 2022</A><U>;</U> <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390022018329/ea158123ex99-1_inspiratech.htm">April
6, 2022</A> (with respect to the first two paragraphs and the section titled &ldquo;Forward-Looking Statement Disclaimer&rdquo; in the
press release attached as Exhibit 99.1 to the Form 6-K), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390022028101/ea160303ex99-1_inspiratech.htm">May
19, 2022</A> (with respect to the first paragraph and the sections titled &ldquo;Highlights,&rdquo; &ldquo;Financial Results for the Three
Months Ended March 31, 2022,&rdquo; &ldquo;Balance Sheet highlights,&rdquo; &ldquo;Forward-Looking Statement Disclaimer,&rdquo; and the
IFRS financial statements in the press release attached as Exhibit 99.1 to the Form 6-K), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390022037453/ea162499ex99-1_inspiratech.htm">July
6, 2022</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390022037758/ea162568ex99-1_inspiratech.htm">July 7, 2022</A>
(with respect to the first six paragraphs and the section titled &ldquo;Forward-Looking Statement Disclaimer&rdquo; in the press release
attached as Exhibit 99.1 to the Form 6-K), <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390022038384/ea162676ex99-1_inspiratech.htm">July
11, 2022</A> (with respect to the first five paragraphs and the section titled &ldquo;Forward-Looking Statement Disclaimer&rdquo; in the
press release attached as Exhibit 99.1 to the Form 6-K), and <A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390022046322/ea164143-6k_inspiratech.htm" STYLE="-sec-extract: exhibit">August 10, 2022</A>; and</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of our securities contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390022016867/f20f2021ex2-1_inspira.htm">Exhibit 2.1</A> to our Annual Report on Form 20-F for the fiscal year ended December 31, 2021, filed with the SEC on March 31, 2022.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All subsequent annual reports
filed by us pursuant to the Exchange Act on Form 20-F prior to the termination of the offering shall be deemed to be incorporated by reference
to this prospectus and to be a part hereof from the date of filing of such documents. We may also incorporate part or all of any Form
6-K subsequently submitted by us to the SEC prior to the termination of the offering by identifying in such Forms 6-K that they, or certain
parts of their contents, are being incorporated by reference herein, and any Forms 6-K so identified shall be deemed to be incorporated
by reference in this prospectus and to be a part hereof from the date of submission of such documents. Any statement contained in a document
incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus
to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be
incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed,
except as so modified or superseded, to constitute a part of this prospectus. The information we incorporate by reference is an important
part of this prospectus, and later information that we file with the SEC will automatically update and supersede the information contained
in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will provide you without
charge, upon your written or oral request, a copy of any of the documents incorporated by reference in this prospectus, other than exhibits
to such documents which are not specifically incorporated by reference into such documents. Please direct your written or telephone requests
to us at: 2 Ha-Tidhar St., Ra&rsquo;anana, 4366504 Israel, Tel: +972-996-64488; Attention: Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an Israeli company
and are a &ldquo;foreign private issuer&rdquo; as defined in Rule 3b-4 under the Exchange Act. As a foreign private issuer, we are exempt
from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal
shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are not required
under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly
as U.S. companies whose securities are registered under the Exchange Act. However, we file with the SEC, within 120 days after the end
of each fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited
by an independent registered public accounting firm, and submit to the SEC, on a Form 6-K, unaudited quarterly financial information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
at www.inspira-technologies.com. The SEC also maintains a web site that contains information we file electronically with the SEC, which
you can access over the Internet at http://www.sec.gov. Information contained on, or that can be accessed through, our website and other
websites listed in this prospectus do not constitute a part of this prospectus. We have included these website addresses in this prospectus
solely as inactive textual references.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is part of
a registration statement on Form F-3 filed by us with the SEC under the Securities Act. As permitted by the rules and regulations of the
SEC, this prospectus does not contain all the information set forth in the registration statement and the exhibits thereto filed with
the SEC. For further information with respect to us and the Common Shares offered hereby, you should refer to the complete registration
statement on Form F-3, which may be obtained from the locations described above. Statements contained in this prospectus or in any prospectus
supplement about the contents of any contract or other document are not necessarily complete. If we have filed any contract or other document
as an exhibit to the registration statement or any other document incorporated by reference in the registration statement, you should
read the exhibit for a more complete understanding of the document or matter involved. Each statement regarding a contract or other document
is qualified in its entirety by reference to the actual document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>ENFORCEABILITY OF CIVIL LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in the registration
statement of which this prospectus forms a part, a substantial majority of whom reside outside of the United States, may be difficult
to obtain within the United States. Furthermore, because substantially all of our assets and a substantial of our directors and officers
are located outside of the United States, any judgment obtained in the United States against us or any of our directors and officers may
not be collectible within the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been informed by our
legal counsel in Israel, Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), that it may be difficult to assert U.S. securities law
claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws
because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim,
it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable
U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure will also be governed
by Israeli law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to specified time
limitations and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter which, subject to certain exceptions, is
non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including
a monetary or compensatory judgment in a non-civil matter, provided that among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment is obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international law currently prevailing in Israel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment is final and is not subject to any right of appeal;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prevailing law of the foreign state in which the judgment was rendered allows for the enforcement of judgments of Israeli courts;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate service of process has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the liabilities under the judgment are enforceable according to the laws of the State of Israel and the judgment and the enforcement of the civil liabilities set forth in the judgment is not contrary to the law or public policy in Israel nor likely to impair the security or sovereignty of Israel;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment was not obtained by fraud and does not conflict with any other valid judgments in the same matter between the same parties;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment is enforceable according to the laws of Israel and according to the law of the foreign state in which the relief was granted.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a foreign judgment is enforced
by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred
out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli
court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment,
but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated
in Israeli currency ordinarily will be linked to the Israeli CPI plus interest at the annual statutory rate set by Israeli regulations
prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to $5,480,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="img_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Inspira Technologies
Oxy B.H.N. Ltd.&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt; background-color: white"><B>Roth
Capital Partners</B></FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>April 4, 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
























</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !  4,# 2(  A$! Q$!_\0
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MDG*,\34Y*L:3G!.<:4*5:K[.U6<:-.4)3_M7Z./T&O$KZ0O#&8>(=3BOP_\
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M'[:/[6GP7_X+,?#'X5?";]HOXO?#KX;ZEX7_ &:;B]\$>$?&VM:)X:N)]?\
M%NHVNM33:197,5G+)JD"+%?-)$YN$ 27<@"CQ\ERBKG6+GA*5:G0E#"XC%.=
M6-2<7'#QC*4$J?O<TE*R;]U=3T\US.GE6&CB:E*=:,\11PZA3E",E*M)Q4KS
M]VT;7:W?0_OIHJGJ+M'I]\Z,4=+.Z=&4X966!RK ]B" 0?45_FS_ /!.W_@N
M-\7/V3/CW^VE\3_VI?CM\6_CEHWACX8^/M"^"/P7\7^-]7UG3/%/Q9O?BAH-
MGX6M;>WO[B6#1].TG3(]5NM;U6TC$^G^'H[^.SMIYI((1KE.0XK.:&85<)*+
MJ8&&'DL/RSE4Q,L35]E"%.4;0@XN\IRJ-14(RDVE%LSS+.,-E=;!4\3&2AC)
M5DZ_-!0H1H4_:2E43]Z2:M&,:=Y.3C%)N21_I+W^I:=I4'VG4[^RTZVW!/M%
M_=06<&]ONIYMQ)''N;LN[)["K4<D<J)+$Z212*KQR1LKHZ, 5='4E65@0592
M00002*_SC++_ ()Q_P#!=G_@M_I>I?M:?%CXAZ;\/OAYXRAN->^%/A'XO_$'
MQ9\/_!NH:!+<W%]I5A\+_A7X8T3Q0^B>'PLT:Z1XD\4Z7I U^#R-1;7M77-]
M7]D7_!'K]BCXG_L!?L2>$?A-\?/B=K/Q"^+=]J.K^.?B'>ZMXSUCQ;X:\%W>
MHK#%:^"_!VI:W<.EMX;\.:186OVF6TBL[&[UJ?5]0BA$,\<C;9KDF#RO#)_V
MW@L9F,:T:.(R_"0G4]C)QDYWQ%^27L7'DF[6=1\D4I)I99=FV*S#$-?V3BL+
M@94I5:.-Q,H0]K%-*%J-N9.JGS15TU!<TFTTS]5*S=1UK1](0RZMJVFZ7& &
M,FHW]K9(%9BJL7N98EPS J#G!8$#D8K^&[_@KA_P<Q?$S7?B1KG[)G_!+MS.
MT6KGP;JO[1.AZ1)XJ\6^,O$TD_\ 9\FA_ W01:7ENEF+]OL5GXLET_5M3UZY
M5)/#5I8VIM]0U#\_? 7_  0 _P""X_[<>F3_ !,^/OC]_ +^+HYM8%O^U;\;
M_'%UXKU#S[Z2\6*^\&>']+^(>L>&0;JYN;FTTC7M-T)[)0^S3[6*2V$O?AN$
M90PM+&9WFF#R.E72E0I8E.IBZD6DU)T(RBX:-/E<9SBFO:*FWRKCK\3*6(J8
M7*<OQ6;U*+<:M3#VAAH23:LJS34]4US)QC)I\CFES/\ TG+6]L[Z(3V-W;7D
M)P!-:SQ7$1)4, )(7=#E65ASRK ]"#5FO\X'Q+_P25_X.#/^"7TC?&CX ?$W
MQ+\1-(\)0PZCJX_9P^+7B?QU:FQMH5,\>K_!_P :Z5X>U/Q3IMI:1207B6_@
MO6XK:R6?!BMV$C?<,/\ P<5:[^UM_P $I_VQ/AWX]\3O^SM_P4'^%OPWT#4?
M#'B#P/=WG@R'XF6VF?$3P39>(->\#;K@W?AKQK9Z<^I+XK\(P7 'V&>[O]!5
M+".\L=*57A&I45&ME69X+-\'/$4,/6KX7F]K@W7JPI1JXG#7E55&+FI2G!)Q
MBKN/+><73XFIP=6EF. Q>68J%"M7I4<1R^SQ2HTY5)4Z%>RINK)0:C&3=VTE
M+F]V7]6O_!2+X):3\?OV/?BKX"OOA3HWQCU8Q^'M8\)^$M6\'Z9XUN4\16'B
M32HUU70M+U.ROA;ZS9Z/<ZQ$E_9QQWD.GW.HPK,+>XN$D_%7XQ?L;_M-Q>"/
MVKO@=\-?A/XVT[X$_'G]I?XM?M-ZMI_AJSO-->QU+X+?'/3;#P;\._#6@6'V
M<GP?\<O#6G?!_6M$T+3;9='G\,^"/'VJP[8YQ:MD?\&I?[1WQZ_:1_9E_:A\
M0_'SXO?$#XOZWX>^.OA_1]"U3X@>)=2\37VD:7-X TV]FL+"YU.>>6VM9;N1
MKB2"-Q&TQ,FW>S$_U4UQXBMBN'<9B<J;HXKZGB8SYW[94G5Y</7A.G3E)\DH
M2<9*7*I<]V^9*-NJA3P^=X:AF*57#_6:#ARVI.HJ?-6I2A.<8^\I)-./,X\M
MDK.]ZUF'%G:B4%9!;0"16&&#B)0X([$-D$=CQ5FN6U_QSX*\*306_BGQAX6\
M-7%S&9;:#7_$&DZ/-<1!BAD@BU&[MGEC#*5+QJRA@1G((KHK6ZMKVV@O+*X@
MN[2ZBCGMKJUFCN+:X@E4/%-!/$SQ312(0\<D;,CJ0RL00:^;/=)Z*** "BBL
MK2M=T775OGT35],UA-+U*[T;4GTR^MK]+#5[#8+[2[Q[665;?4+(RQK=V<I2
MXMG8)-&C_+0!JT5E0Z[HESJ]]X?M]8TN?7M,M;6]U'18=0M)=6L+.^+BRN[W
M3DE:\M;:[,<@MIYX4BGV-Y3-@UJT %%%% !1110 4444 ?YI?_!I!_RE(\6?
M]FE_%C_U._A#7[^?\'?_ /RCA^"?_9Y'@;_U3?QTK\ _^#2#_E*1XL_[-+^+
M'_J=_"&OW\_X._\ _E'#\$_^SR/ W_JF_CI7ZQFW_)Q<G_P9?_Z8S(_.,M_Y
M(?-/\6-_].X$^"O^#3+_ ()O>#_%-EXV_P""C/Q9\/0:]J_AGQ7>_##]G*TU
M>$W-GHNI:1IEJ_CKXD6UO*6MI]3MFU.S\(^&+QXY'T:>R\2W%L(;S[%<0?W6
MU^'_ /P;E^%++PC_ ,$?/V3;:QFFG76K+XD>*[EYQ&'2]\2_%/QEJMU"AC5
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MKW4+6'Q%X,U>&[#PV'[X?LW_ /!WK^QMXQ\*6$7[3GP8^,'P8^(-O9#^V)?
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MOGO=-\(_"QO[2Z$L\4L<HDMQ)Y<DC?3G[+G[/GCZP\9?LP_%OP7\*O@_\*/
MUW\,-1L?BUKWA/XOZUXN\0?'_0/&G@>SO]-U'Q3IS^"]#BUK7=,\5O)XK74M
M2UG5KZTN=2U.-=2EA>0W !]\Z1^S'^ROHWQ&F^+NB_";X76'Q&M)I?$DOBRS
MTS38[^PNKXRW,GB%8TD^PV%U<,T]T-8CM89VD::X2YWM(Y^B;/4+#4+5;ZPO
MK.^LGW[+NSN8;FU;RF99-MQ"[Q-Y;*ROASL96#8((K^>O3?AKX<\(_L<?LO7
M7A3PE87]U^T5^T/X6\&_&V77O%6JZ!#\1_">E>+/'Z^$_AOXM\>O:Z]>^&O
M$M[H^@^&XM*M-.GT]M,(T06;)J-RTGI?QB^%_P 6?@+\#?VE;JS\(^$O@?\
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M//V=/@_XT'C_ .'7PYM?#GB2&/4(=,DBUOQ+>Z5X?@U:%K?48/#'A[4=8N]
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<N99;F\N;BZGEFFD>2::1V.6KN:* "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !  4,# 2(  A$! Q$!_\0
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MDG*,\34Y*L:3G!.<:4*5:K[.U6<:-.4)3_M7Z./T&O$KZ0O#&8>(=3BOP_\
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M'[:/[6GP7_X+,?#'X5?";]HOXO?#KX;ZEX7_ &:;B]\$>$?&VM:)X:N)]?\
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MU^'_ /P;E^%++PC_ ,$?/V3;:QFFG76K+XD>*[EYQ&'2]\2_%/QEJMU"AC5
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MKW4+6'Q%X,U>&[#PV'[X?LW_ /!WK^QMXQ\*6$7[3GP8^,'P8^(-O9#^V)?
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MOGO=-\(_"QO[2Z$L\4L<HDMQ)Y<DC?3G[+G[/GCZP\9?LP_%OP7\*O@_\*/
MUW\,-1L?BUKWA/XOZUXN\0?'_0/&G@>SO]-U'Q3IS^"]#BUK7=,\5O)XK74M
M2UG5KZTN=2U.-=2EA>0W !]\Z1^S'^ROHWQ&F^+NB_";X76'Q&M)I?$DOBRS
MTS38[^PNKXRW,GB%8TD^PV%U<,T]T-8CM89VD::X2YWM(Y^B;/4+#4+5;ZPO
MK.^LGW[+NSN8;FU;RF99-MQ"[Q-Y;*ROASL96#8((K^>O3?AKX<\(_L<?LO7
M7A3PE87]U^T5^T/X6\&_&V77O%6JZ!#\1_">E>+/'Z^$_AOXM\>O:Z]>^&O
M$M[H^@^&XM*M-.GT]M,(T06;)J-RTGI?QB^%_P 6?@+\#?VE;JS\(^$O@?\
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M//V=/@_XT'C_ .'7PYM?#GB2&/4(=,DBUOQ+>Z5X?@U:%K?48/#'A[4=8N]
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<N99;F\N;BZGEFFD>2::1V.6KN:* "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  4,# 2(  A$! Q$!_\0
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MTI] !1110 4444 %%%% 'S1\!?\ DH4W_7A)_P"A)7H'[0'_ "(UE_V$4_\
M1<E>?_ 7_DH4W_7A)_Z$E>@?M ?\B-9?]A%/_1<E=4OXR.>/\)F!\"/!\$Z3
M^*+V(.\<AALPPX4@?,_UYP/QKW:N'^$,"V_PRTD*2=XD<Y]2[&NXK&H[R9K3
M5HHBN;:&\M9;:XC62&9"CHPR&4C!%?.WPM27P[\9[G1E)\IC<6S#.<JN64_^
M.C\Z^CJ^:]-)3]HHX./^)G(./H:JEJI+R)J;IGTI1116)J>#?%6YEU#X@0Z>
MSXCB2.)!Z%CDG]?TKV[3=.MM)TZ"QM(PD,*!5 [^Y]S7@_Q$;'Q9 _Z:6_\
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M!O!&A@@$&PA!!_W!69JOPQ\':S,9KK1(5E9MS- S1%C[[2*T_!W_ ")6A_\
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9U9V=OI]I':VL8CAC&%4=JGHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
